In a unanimous decision on Monday, an FDA advisory panel recommended the approval of Eli Lilly’s (NYSE:LLY) experimental Alzheimer’s treatment, donanemab, marking a significant advancement in the battle against this debilitating disease.

If the FDA agrees with the panel's recommendation, donanemab will become the second approved drug aimed at treating early-stage Alzheimer's.

Donanemab, a monoclonal antibody drug, is administered monthly via an IV and is intended for use for up to 18 months.

During clinical trials, the drug demonstrated a promising 35% reduction in the progression of Alzheimer's disease among participants aged 60 to 85.

This outcome is notably better compared to the current market option, Eisai and Biogen's Leqembi, which reported a 27% decline over the same treatment period.

However, the panel's endorsement comes with caution due to safety concerns. The trials reported several deaths and other serious adverse events, affecting 21% of the participants.

As a result, experts recommend restricting the use of donanemab to specific subgroups of patients to better manage potential risks.